Abstract:Background: Tyrosyl phosphorylation is carried out by a group of enzymes known as non-receptor protein tyrosine phosphatases (PTPNs). In the current investigation, it is hoped to shed light on the relationships between the expression patterns of PTPN family members and the prognosis of acute myeloid leukemia (AML). Methods:PTPN expression was examined using GEPIA and GEO databases. To investigate the connection between PTPN expression and survival in AML patients, we downloaded data from the Broad TCGA Firehose and Clinical Proteomic Tumor Analysis (CPTAC) of the Cancer Genome Atlas (TCGA). We used quantitative real-time PCR (qRT-PCR) to confirm that essential genes were performed in clinical samples and cell lines. We then used western blot to verify that the genes expressed in the above databases were positive in normal tissues, AML patient samples, and AML cell lines. Next, we investigated associations between genome-wide expression profiles and PTPN6 expression using the GEO datasets. We investigated the interactive exploration of multidimensional cancer genomics using the cBioPortal datasets. Using the DAVID database, a study of gene ontology enrichment was performed. The protein-protein interaction (PPI) network was created using the STRING portal, and the gene-gene interaction network was performed using GeneMANIA. Results: Data from GEO and GEPIA revealed that most PTPN family members were linked to AML. Patients with leukemia have elevated levels of several PTPN members. All of the AML patients’ poor overall survival (OS, p < .05) was significantly linked with higher expression of PTPN1, PTPN6, and PTPN7. Additionally, clinical samples showed that the expression of PTPN 6, PTPN 7, PTPN 13, and PTPN 14 was higher than normal in AML patients (p = .0116, p = .0034, p = .0092, and p = .0057, respectively) and AML cell lines (p = .0004, p = .0035, p = .0357, and p = .0177, respectively). Western blotting results showed that the expression of PTPN6 in AML samples and AML cell lines was significantly higher than that in normal control samples. Conclusion: Differentially expressed PTPN family members were found in AML. The prognosis of patients and PTPN gene expression were shown to be correlated. PTPN6 is one of these members and may be used as an AML diagnostic and prognostic marker.

Targeting Inhibition of TCTP Could Inhibit Proliferation and Induce Apoptosis in AML Cells.

Triptolide Inhibits the Proliferation of Cells from Lymphocytic Leukemic Cell Lines in Association with Downregulation of NF-κB Activity and Mir-16-1*.

High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia from Two Cohorts.

Tet2 Downregulation Promotes Aml Cell Proliferation Via Pim-1 Expression

Inhibitory Cells Proliferation and Induce Cells Apoptosis by TPT on HL-60 Cell by C-Myc

The TPO/c-MPL Pathway in the Bone Marrow may Protect Leukemia Cells from Chemotherapy in AML Patients

Aberrant expression of TCTP protein inhibits cell apoptosis by up-regulating Bcl-xL in human pancreatic cancer

Targeting protein tyrosine phosphatase non-receptor type 2 with a novel inhibitor for AML therapy

TCTP protein degradation by targeting mTORC1 and signaling through S6K, Akt, and Plk1 sensitizes lung cancer cells to DNA-damaging drugs

MiR-20a-5p Functions As a Potent Tumor Suppressor by Targeting PPP6C in Acute Myeloid Leukemia

High Expression of Microtubule-associated Protein TBCB Predicts Adverse Outcome and Immunosuppression in Acute Myeloid Leukemia

Biological role and expression of translationally controlled tumor protein (TCTP) in tumorigenesis and development and its potential for targeted tumor therapy

2559 Role of tissue non-specific alkaline phosphatase (TNAP) in promoting the survival of acute myeloid leukemia (AML) cells within the bone marrow microenvironment

High Expression of CPT 1 A Predicts Adverse Outcomes : A Potential Therapeutic Target for Acute Myeloid Leukemia

Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia

Paclitaxel mediates the PI3K/AKT/mTOR pathway to reduce proliferation of FLT3‐ITD + AML cells and promote apoptosis

High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia

Comprehensive Analysis of PTPN Family Expression and Prognosis in Acute Myeloid Leukemia

Therapeutic Targeting of TP53-mutated Acute Myeloid Leukemia by Inhibiting HIF-1α with Echinomycin

Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199

Antineoplastic Effects Of Cpptl Via The Ros/Jnk Pathway In Acute Myeloid Leukemia